All News

The #scleroderma-like pattern on NVC is observed in pts with #dermatomyositis and MCTD It consists of a combination of giant capillaries, some microhemorrhages, severe capillary loss and angiogenesis @RheumNow #ACR24 @rheumarhyme https://t.co/WO9BOYn4ir

Links:

sheila RHEUMarampa ( View Tweet)
#Scleroderma #molecular #signatures in #skin predict long term outcomes 👇worst with inflammatory signature This may have clinical and trial applicability Nice work! Abst0711 #ACR24 @RheumNow @ACRheum https://t.co/3CFxu6bACu

Links:

Janet Pope Janetbirdope ( View Tweet)
Sullivan et al. Vasculitis in VEXAS. 81 patients. 27% vasculitis. Cutaneous SVV 20%, AAV 2.5%, cutaneous MVV 2.5%, LVV 2.5%. @RheumNow #ACR24 Abstr#2651 https://t.co/AV3RcuSKpV https://t.co/xrax025TzP

Links:

Richard Conway RichardPAConway ( View Tweet)
Sullivan et al. Vasculitis in VEXAS. 81 patients. 27% vasculitis. Cutaneous SVV 20%, AAV 2.5%, cutaneous MVV 2.5%, LVV 2.5%. @RheumNow #ACR24 Abstr#2651 https://t.co/AV3RcuSKpV https://t.co/xrax025TzP

Links:

Richard Conway RichardPAConway ( View Tweet)
Disseminated acanthamoeba : pt with modular painful skin lesions on his palms and scalp— initially dx’d with a cutaneous vasculitis- he got worse with immunosuppression. Imaging and histology shown #ThievesMarket #ACR24 @RheumNow https://t.co/FjJ0Sk0Kxt

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Dr. CStone et al. assessed nailfold dermoscopy in distinguishing DM from SLE Almost all DM pts had nailfold changes in at least 1 digit vs. SLE & majority of DM pts had nailfold changes in all 10 digits Dermoscopy is a simple alternative to capillaroscopy @rheumNow #ACR24 ab2404 https://t.co/6tEXAlX7lt

Links:

sheila RHEUMarampa ( View Tweet)
TYK2/JAK1 in Dermato? Interesting pre-clinical study of brepocitinib... but we really just need clinical data Glad to see this is headed straight to a Phase 3! Hoping they allow IVIG: has been a problem with many/most/all? recent dermato studies #ACR24 @RheumNow Abstr#0882 https://t.co/KS8fTMBpPR

Links:

Mike Putman EBRheum ( View Tweet)
back, LBP, spine, AS

Difficult to Manage Axial Spondyloarthritis

d Adela Castro, MD

Studies show that patients with difficult-to-manage axSpA have a higher disease activity; however, the lack of a consensus definition led researchers and clinicians to utilize their own proposed definition, resulting in variability of the characteristics of non-responders.

Read Article
psA.fil_.Hands_.jpg

Evaluation of Bimekizumab in PsA

d Antoni Chan, MD, PhD

Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2 year data on BKZ at #ACR24, and this is a summary of four studies being presented this year at ACR24.

Read Article

LTE of deucravacitinib trials in psoriasis. Remarkable & frankly surprising (to me) persistence of benefit Very encouraging for patients who start TYKs, looks like those who respond may have prolonged benefit #ACR24 @RheumNow Abstr#0290 #ACRBest https://t.co/kao4vqpPTQ

Links:

Mike Putman EBRheum ( View Tweet)
🚨Therapeutic target in PsO? Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO). - HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4. - Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI

Links:

Adela Castro AdelaCastro222 ( View Tweet)
🚨Therapeutic target in PsO? Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO). - HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4. - Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Taiwan claims data study of 135 230 patients who received antineoplastic medications, found that immune checkpoint inhibitors use was associated with a 2-fold increased risk of developing psoriasis (HR 2.43). https://t.co/m5eGT56W12 https://t.co/h5FjQpHOpF

Links:

Dr. John Cush RheumNow ( View Tweet)
COVID.virus_.corona.jpg (keep)

COVID-19 and Long-Term Risk of Autoimmune and Autoinflammatory Disorders

d Jack Cush, MD

A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.

Read Article
Iberdomide Efficacy in Cutaneous Lupus berdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).… https://t.co/2LtBDOIBrN https://t.co/giVDgZBiyk
Dr. John Cush RheumNow ( View Tweet)
Psoriasis pts w/ Arthralgia referred for Rheum Eval - 1419 referred pts, 8.4% (119) met at risk for PsA criteria, and 29% (35) developed PsA w/in 1yr. Predictors included +FHx PsO, Ultrasound synovitis or enthesopathy findings, & low tender joint count. https://t.co/Fxgiu6D72j https://t.co/b8dMCOC18F

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Happy Diwali (11.1.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Cutaneous.lupus.SLE.Face.dermnetnz

Iberdomide Efficacy in Cutaneous Lupus

d Jack Cush, MD

Iberdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).

Read Article
dupuytrens

Treatment Options for Dupuytren’s Contracture

d Jack Cush, MD

The NEJM reports that in a randomized, controlled, head to head trial, collagenase injections were non-inferior to limited fasciectomy in the treatment of Dupuytren’s contracture.

Read Article
RheumNow Podcast square

Blue Collar Arthritis (10.25.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.